5:35 PM
 | 
Aug 20, 2014
 |  BC Extra  |  Clinical News

NovaBay falls after dropping auriclosene for conjunctivitis

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) was off $0.44 (35%) to $0.81 on Wednesday after discontinuing development of an ophthalmic formulation of auriclosene ( NVC-422) to treat adenoviral conjunctivitis. The decision came after the product missed the primary and...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >